Nilufer Ertekin-Taner

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme
    Anthony DelleDonne
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL 32224, USA
    Mol Neurodegener 4:39. 2009
  2. ncbi Genetics of Alzheimer disease in the pre- and post-GWAS era
    Nilufer Ertekin-Taner
    Mayo Clinic Florida, Departments of Neurology and Neuroscience, 4500 San Pablo Road, Birdsall 210, Jacksonville, FL 32224 USA
    Alzheimers Res Ther 2:3. 2010
  3. ncbi Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease
    Nilufer Ertekin-Taner
    Mayo Clinic Florida, Departments of Neurology and Neuroscience, 4500 San Pablo Road, Birdsall 210, Jacksonville, Florida 32224 USA
    Mol Neurodegener 6:31. 2011
  4. ncbi Genetics of Alzheimer's disease: a centennial review
    Nilufer Ertekin-Taner
    Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Neurol Clin 25:611-67, v. 2007
  5. ncbi Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees
    Nilufer Ertekin-Taner
    Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Hum Mol Genet 12:3133-43. 2003
  6. ncbi Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease
    Nilufer Ertekin-Taner
    Mayo Clinic Jacksonville, Department of Neuroscience, Jacksonville, FL, USA
    Hum Mutat 23:334-42. 2004
  7. ncbi Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene
    Nilufer Ertekin-Taner
    Department of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Hum Mol Genet 14:447-60. 2005
  8. ncbi Association of common KIBRA variants with episodic memory and AD risk
    Jeremy D Burgess
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
    Neurobiol Aging 32:557.e1-9. 2011
  9. ncbi Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease
    Minerva M Carrasquillo
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA
    Nat Genet 41:192-8. 2009
  10. ncbi Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer disease
    F Zou
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Neurology 74:480-6. 2010

Research Grants

  1. Mapping Novel Genes for Late-Onset Alzheimer's Disease
    Nilufer Ertekin Taner; Fiscal Year: 2007
  2. Genome wide association study of gene expression levels in Alzheimer's disease
    Nilufer Ertekin Taner; Fiscal Year: 2009
  3. Genome wide association study of gene expression levels in Alzheimer's disease
    Nilufer Ertekin Taner; Fiscal Year: 2010

Collaborators

Detail Information

Publications10

  1. ncbi Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme
    Anthony DelleDonne
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL 32224, USA
    Mol Neurodegener 4:39. 2009
    ..abstract:..
  2. ncbi Genetics of Alzheimer disease in the pre- and post-GWAS era
    Nilufer Ertekin-Taner
    Mayo Clinic Florida, Departments of Neurology and Neuroscience, 4500 San Pablo Road, Birdsall 210, Jacksonville, FL 32224 USA
    Alzheimers Res Ther 2:3. 2010
    ..Potential approaches that could provide further insight into the genetics of AD in the post-GWAS era are also discussed...
  3. ncbi Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease
    Nilufer Ertekin-Taner
    Mayo Clinic Florida, Departments of Neurology and Neuroscience, 4500 San Pablo Road, Birdsall 210, Jacksonville, Florida 32224 USA
    Mol Neurodegener 6:31. 2011
    ....
  4. ncbi Genetics of Alzheimer's disease: a centennial review
    Nilufer Ertekin-Taner
    Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Neurol Clin 25:611-67, v. 2007
    ..The future directions for genetic research in AD as a common and complex condition are also discussed...
  5. ncbi Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees
    Nilufer Ertekin-Taner
    Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Hum Mol Genet 12:3133-43. 2003
    ..These findings indicate that VR22 has variant(s) which influence Abeta42 and contribute to the previously reported linkage for plasma Abeta42 in LOAD families...
  6. ncbi Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease
    Nilufer Ertekin-Taner
    Mayo Clinic Jacksonville, Department of Neuroscience, Jacksonville, FL, USA
    Hum Mutat 23:334-42. 2004
    ..007) in our family series. These results provide strong evidence for pathogenic variant(s) in the 276-kb region harboring IDE that influence intermediate AD phenotypes and risk for AD...
  7. ncbi Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene
    Nilufer Ertekin-Taner
    Department of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Hum Mol Genet 14:447-60. 2005
    ..PLAU_1 is a plausible pathogenic mutation that could act by increasing Abeta42, but additional biological experiments are required to show this definitively...
  8. ncbi Association of common KIBRA variants with episodic memory and AD risk
    Jeremy D Burgess
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
    Neurobiol Aging 32:557.e1-9. 2011
    ..06) but not cerebellum. These results suggest a modest role for KIBRA as a cognition and AD risk gene, and also highlight the multifactorial complexity of its genetic associations...
  9. ncbi Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease
    Minerva M Carrasquillo
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA
    Nat Genet 41:192-8. 2009
    ..0 x 10(-7)) and 1.26 (95% CI = 1.05-1.51) for female heterozygotes (P = 0.01) compared to female noncarriers. For male hemizygotes (P = 0.07) compared to male noncarriers, the odds ratio was 1.18 (95% CI = 0.99-1.41)...
  10. ncbi Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer disease
    F Zou
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Neurology 74:480-6. 2010
    ..Late-onset Alzheimer disease (LOAD) is a common disorder with a substantial genetic component. We postulate that many disease susceptibility variants act by altering gene expression levels...

Research Grants4

  1. Mapping Novel Genes for Late-Onset Alzheimer's Disease
    Nilufer Ertekin Taner; Fiscal Year: 2007
    ..These studies could potentially provide new insights to the pathogenesis of AD, lead to the discovery of novel therapeutic targets and allow for the identificationof "at risk" people by using plasma A6 as a biomarker. ..
  2. Genome wide association study of gene expression levels in Alzheimer's disease
    Nilufer Ertekin Taner; Fiscal Year: 2009
    ..Our proposal is aimed at the discovery of AD risk variants that work through regulation of gene expression using a genome-wide association study design. ..
  3. Genome wide association study of gene expression levels in Alzheimer's disease
    Nilufer Ertekin Taner; Fiscal Year: 2010
    ..Our proposal is aimed at the discovery of AD risk variants that work through regulation of gene expression using a genome-wide association study design. ..